Literature DB >> 19641668

Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction.

Korff Krause1, Boris Fehse, Kai Jaquet, Claudia Lange, Konstantin Kyriazis, Sigrid Boczor, Axel Zander, Karl-Heinz Kuck.   

Abstract

BACKGROUND: Experimental results from various animal models and preliminary clinical data have indicated the capacity of bone marrow-derived stem cells to home into infarcted heart tissue and promote cardiac repair. Erythropoietin (EPO) has been shown to increase the number of active endothelial progenitor cells in humans.
OBJECTIVE: To determine if mobilization of hematopoietic progenitor cells (CD34-positive [CD34+], CD117+ or CD133+ cells) into peripheral blood represents a physiological reaction during acute myocardial infarction (AMI) and if EPO is involved in the regulation of this process.
METHODS: Peripheral blood samples taken from 10 patients with AMI, seven patients with angina pectoris (AP) and five patients without coronary artery disease who underwent coronary angiography (controls) were analyzed for the presence of CD34+, CD117+ or CD133+ cells using flow cytometry. In addition, EPO plasma levels were determined by an ELISA. Samples were drawn between days 1 and 3 and days 4 and 8 after ischemic events.
RESULTS: Increased mean values of CD34+ and CD133+ cells were found in patients with either AMI or AP compared with the control group. Subjects with AMI had augmented cell counts of CD117+ and CD34+ progenitor cells compared with patients with AP. EPO levels were higher in patients with AMI or AP compared with the control group.
CONCLUSIONS: AMI in humans appears to serve as a stimulus for CD117+ and CD34+ progenitor cell mobilization. Increased EPO levels may play a role in the regulation of this process.

Entities:  

Keywords:  Cell mobilization; Erythropoietin; Myocardial infarction; Progenitor cells; Stem cells

Year:  2005        PMID: 19641668      PMCID: PMC2716230     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  23 in total

1.  Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance.

Authors:  A Kranz; C Rau; M Kochs; J Waltenberger
Journal:  J Mol Cell Cardiol       Date:  2000-01       Impact factor: 5.000

2.  Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo.

Authors:  Sui Zhang; Dachun Wang; Zeev Estrov; Sean Raj; James T Willerson; Edward T H Yeh
Journal:  Circulation       Date:  2004-12-13       Impact factor: 29.690

3.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

Authors:  U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

4.  Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.

Authors:  M Vasa; S Fichtlscherer; K Adler; A Aicher; H Martin; A M Zeiher; S Dimmeler
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

5.  Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.

Authors:  S Shintani; T Murohara; H Ikeda; T Ueno; T Honma; A Katoh; K Sasaki; T Shimada; Y Oike; T Imaizumi
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

6.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Authors:  T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

7.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Authors:  M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

9.  Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.

Authors:  A A Kocher; M D Schuster; M J Szabolcs; S Takuma; D Burkhoff; J Wang; S Homma; N M Edwards; S Itescu
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

10.  Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation.

Authors:  Jens M Nygren; Stefan Jovinge; Martin Breitbach; Petter Säwén; Wilhelm Röll; Jürgen Hescheler; Jalal Taneera; Bernd K Fleischmann; Sten Eirik W Jacobsen
Journal:  Nat Med       Date:  2004-04-25       Impact factor: 53.440

View more
  1 in total

Review 1.  Pharmacotherapy for end-stage coronary artery disease.

Authors:  Neel R Sodha; Louis M Chu; Munir Boodhwani; Frank W Sellke
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.